# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

E. Applicant: Response Biomedical Corporation

F. Proprietary and Established Names: RAMP® RSV Assay

# G. Regulatory Information:

1. Regulation section: 21 CFR 866.3480 – Respiratory Syncytial Virus Serological Reagents

2. Classification: Class I

3. Product code: GQG

4. Panel: Microbiology (83)

# H. Intended Use:

1. Intended use(s):

The RAMP RSV Assay is a qualitative immunochromatographic test for the detection of Respiratory Syncytial Virus (RSV) F-protein antigens in nasal wash/aspirate, nasopharyngeal aspirate and nasopharyngeal swab samples. It is an in vitro diagnostic assay that aids in the rapid diagnosis of RSV infections in symptomatic patients 21 years of age and younger. A negative test is presumptive and it is recommended that all negative results be confirmed by cell culture or direct specimen fluorescence assay (DSFA). Negative results do not preclude RSV infection and should not be used as the sole basis for treatment or other management decisions. The test is intended for professional use.

2. Indication(s) for use: Same as Intended Use   
3. Special conditions for use statement(s): For prescription use only   
4. Special instrument requirements: To be used only with the RAMP® 200 Reader

# I. Device Description:

The RAMP RSV Assay consists of the following components:

RAMP RSV test cartridges, RAMP RSV Assay tips, RAMP RSV sample buffer vials, disposable droppers, transfer device, RSV positive control swab, RSV negative control swab, lot card, package insert, and procedure card.

The device requires the following components which are not provided as part of the assay:

RAMP 200 reader, Transport Media and Specimen collection materials

The RAMP Assay Tip contains test-specific reagents. The supplied fixed volume transfer device and the RAMP Assay Tip are used to mix the test-specific reagents with the respiratory sample. Using the same transfer device and tip, an aliquot of the prepared sample is introduced to the sample well of the RAMP Test Cartridge. The RAMP Test Cartridge is a single-use; disposable, plastic housing that encloses an analyte-specific immunochromatographic assay strip. Sample is metered onto the assay strip by a pad at the bottom of the sample well. The assay strip is a Mylarbacked nitrocellulose membrane, near the terminal end of which are two closely spaced capture antibody zones, one of which is analyte-specific and the other of

which is an internal standard. An absorbent pad at the terminal end of the assay strip soaks up excess sample. A section of the bottom of the Test Cartridge is open so the Reader can scan the test strip

![](images/0912d80103c58bcf165604a1c867d6a9c713a1d323272584471722c4d58a1ff7.jpg)

# J. Substantial Equivalence Information:

1. Predicate device name(s): Quidel QuickVue RSV Assay

2. Predicate K number(s): K070747

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The RAMP RSV Assay is a qualitativeimmunochromatographic test for the detectionof Respiratory Syncytial Virus (RSV) F-protein antigens in nasal wash/aspirate,nasopharyngeal aspirate and nasopharyngealswab samples. It is an in vitro diagnosticassay that aids in the rapid diagnosis of RSVinfections in symptomatic patients 21 years ofage and younger. A negative test ispresumptive and it is recommended that allnegative results be confirmed by cell cultureor direct specimen fluorescence assay(DSFA). Negative results do not precludeRSV infection and should not be used as thesole basis for treatment or other managementdecisions. The test is intended for professionaluse.</td><td colspan="1" rowspan="1">The QuickVue RSV test is a dipstickimmunoassay, which allows for therapid, qualitative detection ofRespiratory Syncytial virus (RSV)antigen (viral fusion protein) directlyfrom nasopharyngeal swab,nasopharyngeal aspirate, ornasal/nasopharyngeal wash specimensfor symptomatic pediatric patients(Eighteen years of age and younger).The test is intended for use as an aid inthe diagnosis of acute RespiratorySyncytial viral infections. It isrecommended that negative test resultsbe confirmed by cell culture. Negativeresults do not preclude RSV infectionand it is recommended that they not beused as the sole basis for treatment orother management decisions. The test isintended for professional and laboratoryuse.</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Nasal wash, nasopharyngeal aspirate, andnasopharyngeal swab specimens</td><td colspan="1" rowspan="1">Nasal/ Nasopharyngeal wash,nasopharyngeal aspirate, andnasopharyngeal swab specimens</td></tr><tr><td colspan="1" rowspan="1">Target Antigen</td><td colspan="1" rowspan="1">RSV-F antigen</td><td colspan="1" rowspan="1">RSV-F antigen</td></tr><tr><td colspan="1" rowspan="1">Antibodies</td><td colspan="1" rowspan="1">Two mouse monoclonal antibodiesrecognizing the F- protein of RSV</td><td colspan="1" rowspan="1">Mouse monoclonal antibodiesrecognizing the F- protein</td></tr><tr><td colspan="1" rowspan="1">Test Time</td><td colspan="1" rowspan="1">15 minutes</td><td colspan="1" rowspan="1">15 minutes</td></tr><tr><td colspan="1" rowspan="1">Reagent Stability</td><td colspan="1" rowspan="1">In sealed pouch: Up to the stated expirationdate stored at 15-30°C. Do not remove frompouch until ready to use. Do not freeze.</td><td colspan="1" rowspan="1">Store the kit at room temperature, 15-30°C, out of direct sunlight. Kitcontents are stable until the expirationdate printed on the outer box. Do notfreeze</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">RAMP 200 Reader</td><td colspan="1" rowspan="1">None</td></tr><tr><td colspan="1" rowspan="1">AutomatedProcessing</td><td colspan="1" rowspan="1">Instrument transport of test cartridgewithin reader is the only moving step. Nointernal liquid handling.</td><td colspan="1" rowspan="1">Visual results appear on the test strip,no automation</td></tr><tr><td colspan="1" rowspan="1">Automated Analysis</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Quality Controls</td><td colspan="1" rowspan="1">Provided in every Test Cartridge. Built inperformance controls for routine QCrequirements. A comparison of theinternal standard and the assay resultindicates that sufficient properly mixedsample was applied to the test device andthat unbound fluorescent label washedsufficiently from the detection zone, andthe device was inserted and read properlyby the instrument. Backgroundfluorescence measurement serves as anegative control. Reader controls alsoprevent a used or expired cartridge frombeing read by the reader. Antibodyquality, system function and assay timingare checked on each assay run. Anunacceptable result from the controldisplays a warning message without a testresult on the instrument indicating thatthe test should be repeated.</td><td colspan="1" rowspan="1">Provided on every test strip. The two-color result format provides a simpleinterpretation for positive and negativeresults. The appearance of a blueprocedural Control Line providesseveral forms of positive control bydemonstrating sufficient flow hasoccurred and the functional integrity ofthe Test Strip was maintained. If theblue procedural Control Line does notdevelop within 15 minutes, the testresult is considered invalid. A built-innegative control is provided by theclearing of red background color,verifying that the test has beenperformed correctly. Within 15minutes, the result area should be whiteto light pink and allow the clearinterpretation of the test result. Ifbackground color remains andinterferes with interpretation of the testresult, the result is considered invalid</td></tr><tr><td colspan="1" rowspan="1">System QualityControls</td><td colspan="1" rowspan="1">A built-in Internal Quality Control (IQC)function performs an automated test of allReader analytical systems on a scheduledor operator determined basis to provide arecord of proper Reader functionality. Forcomplete quality control of the systemrefer to the Operator's Manual</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Lot card contains calibration andexpiration information and is suppliedwith every kit. System will not process</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">cartridge if lot card information is notstored in instrument.</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Method Comparison</td><td colspan="1" rowspan="1">vs. Viral culture and DSFA</td><td colspan="1" rowspan="1">vs. Viral Culture</td></tr></table>

# K. Standard/Guidance Document referenced (if applicable):

Not Applicable

# L. Test Principle:

The ${ \mathrm { R A M P } } ^ { \mathrm { \textregistered } }$ RSV Assay is a qualitative immunochromatographic test that utilizes the ${ \mathrm { R A M P } } ^ { \mathrm { \textregistered } }$ 200 Reader for the identification of the presence of RSV F-protein antigens in nasal wash/aspirate, nasopharyngeal aspirate (NP aspirate) and nasopharyngeal swab (NP swab) samples.

A wash/aspirate or swab sample is added to the Sample Buffer. This sample is then mixed with the Assay Tip containing fluorescent-dyed particles conjugated to RSV specific antibodies and applied into the sample well of the Test Cartridge. The sample migrates along the strip.

Fluorescent-dyed particles coated with anti-RSV antibodies bind to RSV F-protein antigens, if present in the sample. As the sample migrates along the strip, RSV-bound particles are captured at the detection zone which is coated with monoclonal antibodies anti RSV-F. Excess fluorescent-dyed particles are captured at the internal standard zone which is coated with goat anti-mouse IgG.

The Reader then measures the amount of fluorescence emitted by the complexes at the detection zone and at the internal standard zone. The instrument calculates a ratio $( \mathrm { R A M P } ^ { \mathrm { \textregistered } }$ Ratio) of the detection zone fluorescence reading to the internal standard zone fluorescence reading. The Reader then compares these ratios to pre-defined threshold limits to determine a positive or negative result for RSV in the tested sample. The $\mathrm { R A M P } ^ { \textregistered } 2 0 0$ is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength of $5 6 0 \mathrm { n m }$ and an emission wavelength of $6 1 0 \mathrm { n m }$ .

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The precision and reproducibility of the RAMP RSV Assay was evaluated using a panel consisting of a high negative RSV sample, a limit of detection (LoD) RSV sample (low positive), and a $2 \mathbf { x }$ LoD RSV sample (moderate positive). The RSV strain used to prepare the samples was RSV A (A-2)

(ATCC VR-1540) following viral titer determinations. To evaluate reproducibility, multiple operators at multiple sites tested each of the three precision samples on 5 different days. Testing at Site 2 was performed in a point-of-care (POC) setting (pediatric clinic, under CLIA umbrella of the hospital). At one site (Site 3), to evaluate precision, operators tested each of the three precision samples an additional 7 days for a total of 12 days. There was $9 9 . 2 \%$ agreement (393/396) with the expected test results for all specimens tested, with no significant differences within run (same operator on same day) between run, operators or sites. The RAMP RSV Assay is a qualitative assay based on numerical RAMP Ratio values.

<table><tr><td rowspan=2 colspan=1>−</td><td rowspan=1 colspan=1>PanelMember ID</td><td rowspan=1 colspan=1>RSVHighNegative</td><td rowspan=1 colspan=1>RSVLowPositive</td><td rowspan=1 colspan=1>RSVModeratePositive</td><td rowspan=2 colspan=1>TotalAgreementAll (%)</td></tr><tr><td rowspan=1 colspan=1>Viral Titer(TCID50/mL)</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>1200</td><td rowspan=1 colspan=1>2400</td></tr><tr><td rowspan=3 colspan=1>Site 1</td><td rowspan=1 colspan=1>Agreement</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=3 colspan=1>90/90 (100%)</td></tr><tr><td rowspan=1 colspan=1>MeanRAMPRatio* Value</td><td rowspan=1 colspan=1>1176</td><td rowspan=1 colspan=1>3226</td><td rowspan=1 colspan=1>5460</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>11%</td><td rowspan=1 colspan=1>11%</td><td rowspan=1 colspan=1>9%</td></tr><tr><td rowspan=3 colspan=1>Site 2</td><td rowspan=1 colspan=1>Agreement</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=3 colspan=1>89/90 (98.9%)</td></tr><tr><td rowspan=1 colspan=1>MeanRAMPRatio Value</td><td rowspan=1 colspan=1>1209</td><td rowspan=1 colspan=1>3273</td><td rowspan=1 colspan=1>5600</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>13%</td><td rowspan=1 colspan=1>14%</td><td rowspan=1 colspan=1>18%</td></tr><tr><td rowspan=3 colspan=1>Site 3</td><td rowspan=1 colspan=1>Agreement</td><td rowspan=1 colspan=1>71/72</td><td rowspan=1 colspan=1>71/72</td><td rowspan=1 colspan=1>72/72</td><td rowspan=3 colspan=1>214/216(99.1%)</td></tr><tr><td rowspan=1 colspan=1>MeanRAMPRatio Value</td><td rowspan=1 colspan=1>1330</td><td rowspan=1 colspan=1>3615</td><td rowspan=1 colspan=1>6193</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>17%</td><td rowspan=1 colspan=1>12%</td><td rowspan=1 colspan=1>11%</td></tr><tr><td rowspan=4 colspan=1>b</td><td rowspan=1 colspan=1>TotalAgreement</td><td rowspan=1 colspan=1>131/132(99.2%)</td><td rowspan=1 colspan=1>130/132(98.5%)</td><td rowspan=1 colspan=1>132/132(100%)</td><td rowspan=1 colspan=1>393/396(99.2%)</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>95.8 - 99.9%</td><td rowspan=1 colspan=1>94.6 - 99.6%</td><td rowspan=1 colspan=1>97.1 - 100%</td><td rowspan=1 colspan=1>97.8 - 99.7%</td></tr><tr><td rowspan=1 colspan=1>OverallMeanRAMP Ratio</td><td rowspan=1 colspan=1>1268</td><td rowspan=1 colspan=1>3449</td><td rowspan=1 colspan=1>5892</td><td rowspan=2 colspan=1>→</td></tr><tr><td rowspan=1 colspan=1>Overall% CV</td><td rowspan=1 colspan=1>16%</td><td rowspan=1 colspan=1>13%</td><td rowspan=1 colspan=1>14%</td></tr></table>

b. Linearity/assay reportable range: Not Applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Not Applicable   
d. Detection limit:

The RAMP RSV Assay was evaluated for analytical sensitivity and reactivity after viral titer was determined by testing 6 strains of RSV (RSV A-Long, RSV A (A-2), RSV B CH93 (18)-18, RSV B Wash/18537/62, RSV B WV/14617/85, RSV B9320) at the LoD concentration in either viral transport media (VTM) to simulate a swab sample type or saline solution to simulate a wash sample type. Although the specific RSV strains causing infection in humans can vary year to year, all contain the conserved membrane-bound Fprotein antigens targeted by the RAMP RSV Assay. Analytical sensitivity (LOD) ranged from $\mathrm { \bar { 3 } } . 5 \mathrm { x } 1 \mathrm { \bar { 0 } } ^ { 2 }$ to $> 1 . 7 \mathrm { x } 1 0 ^ { 5 } \mathrm { T C I D } _ { 5 0 } / \mathrm { \dot { m } L }$ .

<table><tr><td rowspan=1 colspan=1>RSV Sample</td><td rowspan=1 colspan=1>LoD Concentration(TCID50/mL)</td><td rowspan=1 colspan=1>RAMP Result</td></tr><tr><td rowspan=1 colspan=1>A-Long in Saline</td><td rowspan=1 colspan=1>6.5x103</td><td rowspan=1 colspan=1>100% RSV Positive</td></tr><tr><td rowspan=1 colspan=1>A-Long in VTM</td><td rowspan=1 colspan=1>2.5x103</td><td rowspan=1 colspan=1>100% RSV Positive</td></tr><tr><td rowspan=1 colspan=1>A (A-2) in Saline</td><td rowspan=1 colspan=1>1.0x103</td><td rowspan=1 colspan=1>100% RSV Positive</td></tr><tr><td rowspan=1 colspan=1>A (A-2) in VTM</td><td rowspan=1 colspan=1>1.2x103</td><td rowspan=1 colspan=1>100% RSV Positive</td></tr><tr><td rowspan=1 colspan=1>B CH93(18)-18 in Saline</td><td rowspan=1 colspan=1>3.5x102</td><td rowspan=1 colspan=1>100% RSV Positive</td></tr><tr><td rowspan=1 colspan=1>B CH93(18)-18 in VTM</td><td rowspan=1 colspan=1>3.5x102</td><td rowspan=1 colspan=1>100% RSV Positive</td></tr><tr><td rowspan=1 colspan=1>B Wash/18537/62 in Saline</td><td rowspan=1 colspan=1>7.0x103</td><td rowspan=1 colspan=1>95% RSV Positive</td></tr><tr><td rowspan=1 colspan=1>B Wash/18537/62 in VTM</td><td rowspan=1 colspan=1>6.0x103</td><td rowspan=1 colspan=1>100% RSV Positive</td></tr><tr><td rowspan=1 colspan=1>B WV/14617/85 in Saline</td><td rowspan=1 colspan=1>5.0x103</td><td rowspan=1 colspan=1>100% RSV Positive</td></tr><tr><td rowspan=1 colspan=1>B WV/14617/85 in VTM</td><td rowspan=1 colspan=1>2.5x103</td><td rowspan=1 colspan=1>100% RSV Positive</td></tr><tr><td rowspan=1 colspan=1>B9320 in ZMC matrix</td><td rowspan=1 colspan=1>&gt; 1.7x105</td><td rowspan=1 colspan=1>90% RSV Positive</td></tr></table>

e. Analytical specificity:

Cross Reactivity:

The analytical specificity of the RAMP RSV Assay was determined by testing a panel consisting of 16 viruses and 17 bacteria that may be present in the nasal cavity or nasopharynx. Bacterial and viral isolates were tested at the concentrations listed after titer determination. None of the organisms tested gave a positive result in the RAMP RSV Assay. Note: RAMP RSV Assay potential cross-reactivity with Chlamydophila pneumoniae has not been determined.

<table><tr><td colspan="1" rowspan="1">Strain/Isolate</td><td colspan="1" rowspan="1">Concentration</td><td colspan="1" rowspan="1">RSV result</td></tr><tr><td colspan="1" rowspan="1">Adenovirus, Type 1</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Adenovirus, Type 7a</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human coronavirus, Strain OC43</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human coronavirus, Strain 229E</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Enterovirus, Type 71</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Epstein Barr Virus</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human Parainfluenza, Type 1</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human Parainfluenza, Type 2</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human Parainfluenza, Type 3</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Influenza A, Brisbane/10/07</td><td colspan="1" rowspan="1">105 EID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Influenza B, Ohio/01/06</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Measles</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human metapneumovirus</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mumps virus</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Human Rhinovirus, Strain 1A</td><td colspan="1" rowspan="1">105 TCID50/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Bordetella pertussis</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium Sp.</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Haemophilus influenzae</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus casei</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Legionella pneumophila</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Moraxella catarrhalis</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mycobacterium tuberculosis, Avirulent</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mycoplasma pneumoniae</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Neisseria meningitidis</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Neisseria sicca</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus, Strain 176</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus epidermidis, Strain 78</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pneumoniae</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pyogenes</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Streptococcus salivarius</td><td colspan="1" rowspan="1">106 cfu/mL</td><td colspan="1" rowspan="1">Negative</td></tr></table>

# Interfering Substances:

Whole blood and a number of other potentially interfering substances (medications and over the counter (OTC) products) that may be present naturally or artificially introduced in the nasal cavity or nasopharynx were evaluated in the RAMP RSV Assay. The substances were added to a simulated negative sample $( 0 . 8 5 \%$ saline), an RSV LoD positive sample and an RSV 2x LoD positive sample and tested in the RAMP RSV Assay. The RSV strain used to prepare the samples was RSV A (A-2), interference was not evaluated with an RSV B strain. The following substances were found to have no effect on the test results of the RAMP RSV Assay when present in positive and negative RSV simulated respiratory samples at the concentrations indicated:

<table><tr><td colspan="1" rowspan="2">Substance Tested</td><td colspan="1" rowspan="2">Conc.Tested</td><td colspan="2" rowspan="1">Negative</td><td colspan="2" rowspan="1">RSV LoD</td><td colspan="2" rowspan="1">RSV 2x LoD</td></tr><tr><td colspan="1" rowspan="1">RAMPResults</td><td colspan="1" rowspan="1">Percent ofMean ControRatio</td><td colspan="1" rowspan="1">RAMPResults</td><td colspan="1" rowspan="1">Percent ofMeanControl Ratiq</td><td colspan="1" rowspan="1">RAMPResults</td><td colspan="1" rowspan="1">Percent ofMeanControl Ratic</td></tr><tr><td colspan="1" rowspan="1">Control Saline (0.85%)only(No interferingsubstance)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">Whole Blood</td><td colspan="1" rowspan="1">2% v/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">118%</td><td colspan="1" rowspan="1">Pos 2/3</td><td colspan="1" rowspan="1">89%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">86%</td></tr><tr><td colspan="1" rowspan="1">Mucin</td><td colspan="1" rowspan="1">1% w/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">123%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">96%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">94%</td></tr><tr><td colspan="1" rowspan="1">Scope® Mouthwash</td><td colspan="1" rowspan="1">40% v/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">117%</td><td colspan="1" rowspan="1">Pos 2/3</td><td colspan="1" rowspan="1">91%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">85%</td></tr><tr><td colspan="1" rowspan="1">Good and Kind™MMouthwash</td><td colspan="1" rowspan="1">40% v/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">122%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">93%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">83%</td></tr><tr><td colspan="1" rowspan="1">Cepacol® Mouth Wash</td><td colspan="1" rowspan="1">40% v/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">128%</td><td colspan="1" rowspan="1">Pos 2/3</td><td colspan="1" rowspan="1">90%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">78%</td></tr><tr><td colspan="1" rowspan="1">Cepacol® Lozenge(Benzocaine)</td><td colspan="1" rowspan="1">30% w/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">115%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">93%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">69%</td></tr><tr><td colspan="1" rowspan="1">Fisherman's Friend®Throat Drop(Menthol)</td><td colspan="1" rowspan="1">30% w/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">107%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">94%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">80%</td></tr><tr><td colspan="1" rowspan="1">Rhinocort® NasalSpray (Budesonide)</td><td colspan="1" rowspan="1">15% v/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">125%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">102%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">76%</td></tr><tr><td colspan="1" rowspan="1">Nasacort® Nasal Spray(Triamcinolone)</td><td colspan="1" rowspan="1">15% v/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">141%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">85%</td></tr><tr><td colspan="1" rowspan="1">Flonase® Nasal Spray(Fluticasone Furoate)</td><td colspan="1" rowspan="1">30% v/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">145%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">85%</td></tr><tr><td colspan="1" rowspan="1">Nasonex® Nasal Spray(Mometasone Furoate)</td><td colspan="1" rowspan="1">15% v/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">134%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">94%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">79%</td></tr><tr><td colspan="1" rowspan="1">Tylenol® Tablets(4-Acetamidophenol)</td><td colspan="1" rowspan="1">20 mg/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">96%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">90%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">81%</td></tr><tr><td colspan="1" rowspan="1">Aspirin® Tablets(Acetylsalicylic Acid)</td><td colspan="1" rowspan="1">30 mg/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">127%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">80%</td></tr><tr><td colspan="1" rowspan="1">Chlor-Tripolon™Tablets(Chloropheniramine)</td><td colspan="1" rowspan="1">10 mg/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">110%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">98%</td></tr><tr><td colspan="1" rowspan="1">Benadry™" AllergyTablet(Diphenhydramine)</td><td colspan="1" rowspan="1">5 mg/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">136%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">107%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">91%</td></tr><tr><td colspan="1" rowspan="1">Delsym® DM CoughSyrup(Dextromethorphan)</td><td colspan="1" rowspan="1">2 mg/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">135%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">121%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">105%</td></tr><tr><td colspan="1" rowspan="1">Robitussin® Syrup(Guaiacol GlycerolEther</td><td colspan="1" rowspan="1">40 mg/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">140%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">89%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">82%</td></tr><tr><td colspan="1" rowspan="1">Phenylpropanol-amine (pure)</td><td colspan="1" rowspan="1">40 mg/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">142%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">96%</td></tr><tr><td colspan="1" rowspan="1">RAMPResults</td><td colspan="1" rowspan="1">Percent ofMean ControRatio</td><td colspan="1" rowspan="1">RAMPResults</td><td colspan="1" rowspan="1">Percent ofMeanControl Ratic</td><td colspan="1" rowspan="1">RAMPResults</td><td colspan="1" rowspan="1">Percent ofMeanControl Ratio</td></tr><tr><td colspan="1" rowspan="1">Afrin® Nasal Spray(Oxymetazoline HCl)</td><td colspan="1" rowspan="1">0.05% v/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">86%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">76%</td></tr><tr><td colspan="1" rowspan="1">Neo-Synephrine®Nasal Spray(Phenylephrine HCl)</td><td colspan="1" rowspan="1">20 mg/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">121%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">87%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">84%</td></tr><tr><td colspan="1" rowspan="1">Otrivin® Saline (NaClw/preservatives)</td><td colspan="1" rowspan="1">1.4% w/v</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">122%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">91%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">94%</td></tr><tr><td colspan="1" rowspan="1">Rebetol® (Ribavirin)</td><td colspan="1" rowspan="1">100ng/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">116%</td><td colspan="1" rowspan="1">Pos 2/3</td><td colspan="1" rowspan="1">92%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">82%</td></tr><tr><td colspan="1" rowspan="1">Relenza® (Zanamivir)</td><td colspan="1" rowspan="1">20 mg/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">89%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">76%</td></tr><tr><td colspan="1" rowspan="1">Rimantadine HCl</td><td colspan="1" rowspan="1">500ng/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">118%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">87%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">85%</td></tr><tr><td colspan="1" rowspan="1">Tamiflu® (OseltamivirPhosphate</td><td colspan="1" rowspan="1">50 mg/mL</td><td colspan="1" rowspan="1">Neg 3/3</td><td colspan="1" rowspan="1">146%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">127%</td><td colspan="1" rowspan="1">Pos 3/3</td><td colspan="1" rowspan="1">108%</td></tr></table>

# $f .$ Assay cut-off:

The kit lot threshold is determined by applying a standard factor to the difference in the mean RAMP Ratios between the negative and the QC standard. This estimated range of the factor was determined though preclinical testing with retrospective positive and negative clinical samples. The value of the factor was found to be optimized at 0.7 and validated by Receiver Operator Curve (ROC) analysis. This lot-specific threshold is then programmed into the lot cards and must be uploaded to the reader when a new kit lot is opened in order to run a test. This factor was then applied to the clinical trial lots to determine the clinical results and will be the standard factor used to generate the lot-specific Ratio Threshold for all manufacturing lots.

2. Comparison studies:

a. Method comparison with reference method: Not Applicable

b. Matrix comparison:

Sample Collection Swab Compatibility:

Four swab materials (see below) were evaluated for compatibility in the RAMP RSV Assay by testing a negative sample (swab alone with no virus present), an RSV LoD positive sample and an RSV 2x LoD positive sample in the RSV test. The RSV strain used to prepare the samples was RSV A (A-2) following titer determination. Each swab was dosed with the appropriate sample and extracted into Copan Universal Transport Media prior to testing in the RAMP RSV Assay. The RAMP RSV Assay is a qualitative assay based on numerical RAMP Ratio values. The $\% C V s$ were calculated for the RAMP Ratios. The negative sample (swab alone) tested negative and all 2x LoD samples tested positive. None of the swabs tested interfered with the performance of the RAMP RSV Assay. Note: In general, calcium alginate swabs are not recommended because they may be cytotoxic to cells and cause viral culture assay inhibition.

<table><tr><td rowspan=2 colspan=1>Swab MaterialTested</td><td rowspan=1 colspan=3>RAMP Results</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>RSV LoD</td><td rowspan=1 colspan=1>RSV 2x LoD</td></tr><tr><td rowspan=1 colspan=1>Foam</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100% Pos</td><td rowspan=1 colspan=1>100% Pos</td></tr><tr><td rowspan=1 colspan=1>Polyester</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>67% Pos</td><td rowspan=1 colspan=1>100% Pos</td></tr><tr><td rowspan=1 colspan=1>Rayon</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>67% Pos</td><td rowspan=1 colspan=1>100% Pos</td></tr><tr><td rowspan=1 colspan=1>Nylon</td><td rowspan=1 colspan=1>100% Neg</td><td rowspan=1 colspan=1>100% Pos</td><td rowspan=1 colspan=1>100% Pos</td></tr><tr><td rowspan=2 colspan=1>Average RAMPRatio% CV</td><td rowspan=2 colspan=1>9%</td><td rowspan=1 colspan=1>21%</td><td rowspan=2 colspan=1>21%</td></tr><tr><td rowspan=1 colspan=1></td></tr></table>

Transport Media Compatibility :

Multiple lots of each of seven commercially available transport media (see below) were evaluated for compatibility in the RAMP RSV Assay by testing a negative sample (transport media only), an RSV LoD positive sample and an RSV 2x LoD positive sample. The RSV strain used to prepare the samples was RSV A (A-2) following titer determination. The RAMP RSV Assay is a qualitative assay based on numerical RAMP Ratio values. The $\% C V s$ were calculated for the RAMP Ratios. None of the tested transport media interfered with the performance of the RAMP RSV Assay.

<table><tr><td colspan="1" rowspan="2">Transport Media Tested</td><td colspan="3" rowspan="1">RAMP Results</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">RSV LoD</td><td colspan="1" rowspan="1">RSV 2x LoD</td></tr><tr><td colspan="1" rowspan="1">Copan: Universal Transport Media(UTM)</td><td colspan="1" rowspan="1">100% Neg</td><td colspan="1" rowspan="1">100% Pos</td><td colspan="1" rowspan="1">100% Pos</td></tr><tr><td colspan="1" rowspan="1">Remel: M4 Media</td><td colspan="1" rowspan="1">100% Neg</td><td colspan="1" rowspan="1">100% Pos</td><td colspan="1" rowspan="1">100% Pos</td></tr><tr><td colspan="1" rowspan="1">Remel: M4-RT Media</td><td colspan="1" rowspan="1">100% Neg</td><td colspan="1" rowspan="1">100% Pos</td><td colspan="1" rowspan="1">100% Pos</td></tr><tr><td colspan="1" rowspan="1">Remel: M5 Media</td><td colspan="1" rowspan="1">100% Neg</td><td colspan="1" rowspan="1">100% Pos</td><td colspan="1" rowspan="1">100% Pos</td></tr><tr><td colspan="1" rowspan="1">Starplex Transport Media</td><td colspan="1" rowspan="1">100% Neg</td><td colspan="1" rowspan="1">100% Pos</td><td colspan="1" rowspan="1">100% Pos</td></tr><tr><td colspan="1" rowspan="1">0.85% Saline Solution</td><td colspan="1" rowspan="1">100% Neg</td><td colspan="1" rowspan="1">93% Pos</td><td colspan="1" rowspan="1">100% Pos</td></tr><tr><td colspan="1" rowspan="1">Phosphate Buffered Saline (PBS)Solution</td><td colspan="1" rowspan="1">100% Neg</td><td colspan="1" rowspan="1">93% Pos</td><td colspan="1" rowspan="1">100% Pos</td></tr><tr><td colspan="1" rowspan="1">Average RAMP Ratio: % CV</td><td colspan="1" rowspan="1">12%</td><td colspan="1" rowspan="1">16%</td><td colspan="1" rowspan="1">14%</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

b. Clinical specificity: Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable):

Prospective Clinical Studies:

The performance of the RAMP RSV Assay was compared to cell culture and DSFA in a prospective study conducted as part of a multi-center trial during the 2008-2009 RSV season. Eight (8) independent laboratories located in distinct geographical regions across the United States (NY, MO(2), MD, OH(2), MA, AR) evaluated the RAMP RSV Assay in parallel with cell culture / DSFA. Testing staff included both laboratory and non-laboratory personnel, and two sites (MO, AR) also performed testing in point-of-care settings (near patient). The sites included an Emergency Department and Pediatric Testing Unit (both under CLIA umbrella of the individual hospital). One thousand, two hundred and seventy nine (1279) fresh specimens were collected from pediatric patients 21 years of age and younger. Of these specimens, valid results were obtained from 1140, with an approximately equal mix of male and female patients. During the clinical study, if either the cell culture or DSFA result was positive for a patient sample, it was determined to be a positive reference result. A reference result was deemed negative only if both, culture and DSFA, were negative

Results with Prospective Nasopharyngeal Swab Samples   

<table><tr><td rowspan=1 colspan=4>NP Swab</td></tr><tr><td rowspan=2 colspan=1>Culture / DSFA</td><td rowspan=1 colspan=3>RAMP RSV</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>127</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>7*</td><td rowspan=1 colspan=1>257</td><td rowspan=1 colspan=1>264</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>272</td><td rowspan=1 colspan=1>391</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>88.2%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>81.4  92.7</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=1>94.6  98.7</td></tr></table>

\* 1 was positive by the RAMP RSV Assay and by the Prodesse ProFlu RT-PCR analysis.

Results with Prospective Nasopharyngeal Aspirate Samples   

<table><tr><td rowspan=1 colspan=4>NP Aspirate</td></tr><tr><td rowspan=2 colspan=1>Culture / DSFA</td><td rowspan=1 colspan=3>RAMP RSV</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>168</td><td rowspan=1 colspan=1>29*</td><td rowspan=1 colspan=1>197</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>15**</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>306</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>183</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>503</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>85.3%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>79.7  89.6</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95.1%</td><td rowspan=1 colspan=1>92.1  97.0</td></tr></table>

\* 8 were negative by the RAMP RSV Assay and by an investigational RT-PCR. $^ { * * } 3$ were positive by the RAMP RSV Assay and by an investigational RT-PCR.

Results with Prospective Nasal Wash / Aspirate Samples   

<table><tr><td rowspan=1 colspan=4>Nasal Wash / Aspirate</td></tr><tr><td rowspan=2 colspan=1>Culture / DSFA</td><td rowspan=1 colspan=3>RAMP RSV</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>11*</td><td rowspan=1 colspan=1>109</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>9**</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>137</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>246</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>89.9%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>82.8  94.3</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>93.4%</td><td rowspan=1 colspan=1>88.0 - 96.5</td></tr></table>

\* 1 was negative by the RAMP RSV Assay and by an investigational RT-PCR. $* * 1$ was positive by the RAMP RSV Assay and by an investigational RT-PCR

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range:

The prevalence of RSV varies each year with epidemics occurring during the fall and winter months in the US. Variables that affect the rate of positivity observed in respiratory testing include: the efficiency and timing of specimen collection, handling and transport of the specimen, the time of year, age of the patient, and local disease prevalence.

The prevalence observed with culture and DSFA during the clinical study (November 2008 – February 2009) was $3 3 . 9 \%$ (443/1306). During the previous U.S. respiratory season (October 2007 – March 2008), the prevalence of RSV was $1 5 . 9 \% 8$ .

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.